STUDresearch · Peptide
B7-33
Also known as
B7-33 relaxin analog · H2 relaxin derivative
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Systemic
SubQ reports
Healing & repair
Systemic research peptide — relaxin-family/RXFP1 signaling, not an organ bioregulator or a proven local scar treatment.
What people say
B7-33 is a relaxin-family research peptide studied for RXFP1 signaling and antifibrotic effects. It is not an organ bioregulator. Recovery/scar discussions are sparse and do not establish human benefit.
Doses people talk about
The existing numerical discussion is retained, not validated. The checked personal log contains ambiguous written units and syringe markings, so it is not silently converted into a dose chart.
How it may feel
There is no dependable signature effect. One SubQ user reported early body/heart/stomach sensations and later fitness/airway improvement while also using BPC/TB; other discussions are still questions or plans.
Experimental SubQ discussion~100–500 mcg SC
Frequency is sporadic/unspecified in the preserved notes, not an established daily bodybuilding template or human protocol.
Half-life & effect duration
- Half-life in the body
- Native B7-33 · serum testAbout 6 minutes
- Modified PEG12 version · serum testAbout 60 minutes
- Felt duration people report
- First few daysBody, heart or stomach sensations in one stacked-use account
- Continued useFitness or airway improvement reported across a 4-week course
Cycles people discuss
Older 10–20 day seasonal-course talk comes from broader bioregulator culture. One B7-33 follow-up described 4 weeks, 5 days on / 2 off; neither that account nor weeks-on/weeks-off lore sets a validated calendar.
Timing
Timing around side effects, training and sleep is discussed, but no after-dose human clock is established. A 6-minute in-vitro serum result is not an injection interval; the 60-minute result belongs to a modified peptide.
Stacks
BPC/TB co-use appears in one completed account. Broader organ-bioregulator stack lists are not B7-33 evidence; multi-agent use makes benefit and adverse-effect attribution difficult.
Watch for
Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The checked research does not establish an in-vivo human bodily half-life.
Native B7-33 degraded with an approximately 6-minute half-life in vitro; the lipidated PEG12 derivative measured about 60 minutes in the same serum assay.
These are degradation measurements outside the body. They cannot establish human SubQ absorption, dosing frequency or the native peptide's in-vivo persistence.
- Praveen et al. — lipidated B7-33 and in-vitro serum stability (opens in a new tab)Full article read via Europe PMC XML: introduction/identity; §2.4 and Figure 5 (native 6 min versus lipidated 60 min); §3.7 human serum at 37°C; conclusion calls for animal PK studies.Human serum is a laboratory matrix, not human pharmacokinetics. Lipidated AcK(PalmGlu)-PEG12-B7-33 is chemically distinct; cellular antifibrotic readouts are not human clinical outcomes.
Felt duration people report
No reproducible after-dose felt duration is established.
One user described first-few-day body/heart/stomach sensations, fitness/airway impressions and a 4-week 5-on/2-off course. A separate calf-scar discussion remained a plan rather than a completed outcome.
Co-use, ambiguous dose units and subjective attribution limit the account. The user's later reason for stopping is not evidence that B7 caused an eye condition or that benefits persisted for a known interval.
- B7-33 — SubQ account and same-author course follow-up (opens in a new tab)November 2025 thread: Frosty_Definition656 first-person replies and later 4-week, 5-days-on/2-off follow-up; BPC/TB co-use, early sensations and stated reason for stopping.Actual visible thread/follow-ups read. Written amounts “0.500mcg” / “0.800mcg” and syringe markings are ambiguous and not converted to 500/800 mcg. Claimed airway clearing is not verified physiology.
- B7-33 peptide — prospective calf-scar discussion (opens in a new tab)Actual posts 1–5: JKVol March 9, 2026 question and March 12 follow-up about a calf-scar/cramp hypothesis; Smont reply explicitly says not used.This is planning/purchase discussion, not a completed benefit report. It cannot establish dose, onset, efficacy or duration.
What people say
- Relaxin-family research narrative: B7-33 is studied for RXFP1 signaling and antifibrotic effects in preclinical settings. Older catalog “normalization” language is a discussion label, not an established organ-restoring or human therapeutic effect. forumlab
- What is thinner: Large modern multi-center RCTs are often absent for the specific peptide brand story. forum
- Recovery narrative: B7-33 is discussed for soft-tissue bounce-back, joint noise, or post-strain continuity. forum
- Local vs systemic mental model: Pin-site lore and whole-body recovery stories often mix. forum
- Time course: Many logs want a 2–4 week checkpoint before calling it. forum
Doses people talk about
- When numbers appear: experimental ~100–500 mcg SC talk — not a validated human protocol. forum
- Frequency: research discussions are sporadic, not a standard daily bodybuilding template. forum
- Honesty: mechanism tweets exceed reproducible dose tables. forum
- Framing: Relaxin-family research peptide. forum
How it may feel
- Days 1–7: Older generic peptide notes list injection-site reactions or GI/mood shifts with oral use, but do not establish those as typical B7-33 experiences or verify oral exposure. One actual SubQ B7-33 account with BPC/TB co-use described moderate body/heart/stomach sensations during the first few days. forum
- Courses: The old 10–20 day courses repeated a few times per year describe broader bioregulator culture, not an established B7-33 calendar. One B7-33 user described fitness/airway improvement with BPC/TB co-use and later reported a 4-week course, 5 days on / 2 off. A separate calf-scar forum discussion remained a plan, not a completed result. forum
- Day 1: Route, sting and GI logistics appear in broader peptide self-logs; their inclusion here does not establish what most B7-33 users feel or prove an immediate benefit. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: A self-log checkpoint in older discussion, not a demonstrated B7-33 onset threshold. Reports are too sparse and confounded to define when benefit should begin. forum
Cycles people discuss
- Course culture: Short-on, long-off seasonal repetition is inherited from broader bioregulator discussion. It is not established as the common B7-33 pattern or as a pharmacology-backed cycle. forum
- Weeks-on / weeks-off discussion: Existing self-protocol lore uses these calendars rather than indefinite daily use, often because of cost and caution. The checked B7-33 follow-up describes 4 weeks with 5 days on / 2 off, not a validated or representative schedule. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Short-peptide lore versus serum assay: Rapid clearance and course-over-steady-state reasoning are assumptions in older discussion. A checked in-vitro human-serum assay at 37°C measured B7-33 degradation t½ at about 6 minutes; a lipidated PEG12 derivative lasted about 60 minutes. Neither is an in-vivo human plasma half-life, and the modified peptide is not native B7-33. forumlab
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Published PK boundary: The inspected serum-stability paper does not establish human in-vivo parent half-life, SubQ absorption or a felt-effect duration. It calls for future animal pharmacokinetic work on the lipidated derivative; human PK should not be inferred from the 6-minute or 60-minute assay values. lab
More on what it is
- Evidence honesty: Much of the English-web discussion is secondary summaries and vendor literature; treat claims cautiously. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for B7-33, not proof it works for you. forum
- What it is: B7-33 is a synthetic single-B-chain derivative of human H2 relaxin, studied for RXFP1 signaling and antifibrotic activity. Its placement in cytomedine/Khavinson-style organ-bioregulator catalogs is a category mix-up, not its molecular identity. Preclinical findings do not establish human treatment benefit. triallab
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Stack context: Organ-system multi-bioregulator combinations belong to the broader catalog culture, not an established B7-33 protocol. The checked B7-33 self-report used BPC/TB too, which prevents clean attribution and does not establish combination safety. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Generally mild claims: Vendor literature often claims good tolerability — independent long-term data limited. forum
- Allergy / unknown impurities: Gray-market risk. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.